Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 20/20 | 0.78 |
| ▸ | ITGAV | P06756 | 20/20 | 0.78 |
| ▸ | ITGA2B | P08514 | 13/20 | 0.78 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8177326 | 0.83 | ITGB3 (0.77) | ITGB3ITGAVITGA2B | |
| SCHEMBL7079514 | 0.81 | ITGB3 (0.55) | ITGB3ITGAVITGA2B | |
| SCHEMBL7919225 | 0.81 | ITGB3 (0.73) | ITGB3ITGAVITGA2B | |
| SCHEMBL8170992 | 0.78 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL7543841 | 0.75 | ITGB3 (1.00) | ITGB3ITGAVITGA2B | |
| SCHEMBL6947112 | 0.75 | ITGB3 (0.47) | ITGB3ITGAVITGA2B | |
| SCHEMBL8181057 | 0.73 | ITGB3 (0.78) | ITGB3ITGAVITGA2B | |
| SCHEMBL6674125 | 0.72 | ITGB3 (0.73) | ITGB3ITGAVITGA2B | |
| SCHEMBL8180742 | 0.71 | ITGB3 (0.77) | ITGB3ITGAVITGA2B | |
| SCHEMBL6950690 | 0.71 | ITGB3 (1.00) | ITGB3ITGAVITGA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | claimed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | claimed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | claimed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | claimed |
| EP-0946180-A4 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORP (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| EP-0946180-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1999-10-06 | — | — | EP | disclosed |
| EP-0906103-A4 | — | — | 1999-04-07 | — | — | EP | disclosed |
| EP-0906103-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-04-07 | — | — | EP | disclosed |
| WO-1998015278-A1 | METHOD FOR STIMULATING BONE FORMATION | SMITHKLINE BEECHAM CORPORATION (US) | 1998-04-16 | — | — | WO | disclosed |
| WO-1997024124-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | ITGB3 11/4885ITGAV 18/4885ITGA2B 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.